Krispy Kreme Inc vs Sana Biotechnology Inc — how do they compare? Krispy Kreme Inc trades at $3.36 (market cap $574.09M), while Sana Biotechnology Inc trades at $3.58 (market cap $994.89M). The key difference: Sana Biotechnology Inc is the larger of the two by market cap, and Krispy Kreme Inc pays a 3.47% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| DNUT | SANA | |
|---|---|---|
Market Cap | $574.09M | $994.89M |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $5.92 |
52-Week Low | $2.92 | $2.68 |
Enterprise Value | $1.77B | $969.08M |
Dividend Yield | 3.47% | — |
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $3.47, up 0.87% today, with a bearish technical signal and mixed earnings history. The company reported a net loss of $515.77M in 2025 despite a gross margin of 75.56%, while analyst consensus leans bullish with 50% buy ratings. Recent news highlights strategic pivots to capital-light models and seasonal product launches to drive engagement.
Outlook remains challenged by persistent losses and high debt, but positive free cash flow in Q1 2026 and international growth potential offer catalysts. Key risks include execution on turnaround plans and competitive pressures in the consumer staples sector.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.
The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.
Trailing returns across standard periods
Latest headlines on both assets
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →